This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

E. Paul MacCarthy, MD, FRCPI
Bayer Corporation West Haven, Conn

JAMA. 1996;275(7):518.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Bayer Corporation believes it acted appropriately in the dissemination of the Dear Doctor letter that Dr Stryer and colleagues refer to in their letter.

It is our position that the letter by an internationally recognized expert in the treatment of hypertension defending CCBs and nifedipine in particular was a physician-to-physician communication that did not promote, or even mention individual brands, and therefore did not fall under the purview of advertising and labeling regulations. The letter restated this expert's well-known position on the study by Dr Psaty and colleagues¹ and was written by him without any remuneration for his time and effort. In fact, this dialogue . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?